Literature DB >> 21622733

Inflammatory stimuli inhibit glucocorticoid-dependent transactivation in human pulmonary epithelial cells: rescue by long-acting beta2-adrenoceptor agonists.

Christopher F Rider1, Elizabeth M King, Neil S Holden, Mark A Giembycz, Robert Newton.   

Abstract

By repressing inflammatory gene expression, glucocorticoids are the most effective treatment for chronic inflammatory diseases such as asthma. However, in some patients with severe disease, or who smoke or suffer from chronic obstructive pulmonary disease, glucocorticoids are poorly effective. Although many investigators focus on defects in the repression of inflammatory gene expression, glucocorticoids also induce (transactivate) the expression of numerous genes to elicit anti-inflammatory effects. Using human bronchial epithelial (BEAS-2B) and pulmonary (A549) cells, we show that cytokines [tumor necrosis factor α (TNFα) and interleukin 1β], mitogens [fetal calf serum (FCS) and phorbol ester], cigarette smoke, and a G(q)-linked G protein-coupled receptor agonist attenuate simple glucocorticoid response element (GRE)-dependent transcription. With TNFα and FCS, this effect was not overcome by increasing concentrations of dexamethasone, budesonide, or fluticasone propionate. Thus, the maximal ability of the glucocorticoid to promote GRE-dependent transcription was reduced, and this was shown additionally for the glucocorticoid-induced gene p57(KIP2). The long-acting β(2)-adrenoceptor agonists (LABAs) formoterol fumarate and salmeterol xinafoate enhanced simple GRE-dependent transcription to a level that could not be achieved by glucocorticoid alone. In the presence of TNFα or FCS, which repressed glucocorticoid responsiveness, these LABAs restored glucocorticoid-dependent transcription to levels that were achieved by glucocorticoid alone. Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622733     DOI: 10.1124/jpet.111.181016

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  CRTC2 Is a Coactivator of GR and Couples GR and CREB in the Regulation of Hepatic Gluconeogenesis.

Authors:  Micah J Hill; Shigeru Suzuki; James H Segars; Tomoshige Kino
Journal:  Mol Endocrinol       Date:  2015-12-10

Review 2.  Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.

Authors:  Robert Newton; Mark A Giembycz
Journal:  Br J Pharmacol       Date:  2016-11-09       Impact factor: 8.739

3.  β-Adrenergic agonists differentially regulate highly selective and nonselective epithelial sodium channels to promote alveolar fluid clearance in vivo.

Authors:  Charles A Downs; Lisa H Kriener; Ling Yu; Douglas C Eaton; Lucky Jain; My N Helms
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-04-13       Impact factor: 5.464

4.  Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide.

Authors:  M M Kelly; E M King; C F Rider; C Gwozd; N S Holden; J Eddleston; B Zuraw; R Leigh; P M O'Byrne; R Newton
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 5.  Important lessons learned from studies on the pharmacology of glucocorticoids in human airway smooth muscle cells: Too much of a good thing may be a problem.

Authors:  Yassine Amrani; Reynold A Panettieri; Patricia Ramos-Ramirez; Dedmer Schaafsma; Klaudia Kaczmarek; Omar Tliba
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

6.  The long-acting β2 -adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent manner.

Authors:  T Joshi; M Johnson; R Newton; M A Giembycz
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

7.  Neutralizing TNFα restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation.

Authors:  L Dejager; K Dendoncker; M Eggermont; J Souffriau; F Van Hauwermeiren; M Willart; E Van Wonterghem; T Naessens; M Ballegeer; S Vandevyver; H Hammad; B Lambrecht; K De Bosscher; J Grooten; C Libert
Journal:  Mucosal Immunol       Date:  2015-03-11       Impact factor: 7.313

Review 8.  Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones.

Authors:  Tonio Pera; Raymond B Penn
Journal:  Pharmacol Ther       Date:  2016-04-23       Impact factor: 12.310

9.  Roles for the mitogen-activated protein kinase (MAPK) phosphatase, DUSP1, in feedback control of inflammatory gene expression and repression by dexamethasone.

Authors:  Suharsh Shah; Elizabeth M King; Ambika Chandrasekhar; Robert Newton
Journal:  J Biol Chem       Date:  2014-04-01       Impact factor: 5.157

10.  Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist.

Authors:  Javier Milara; Anselm Morell; Bea Ballester; Celia Sanz; Jose Freire; Xiaozhong Qian; Maggie Alonso-Garcia; Esteban Morcillo; Julio Cortijo
Journal:  Respir Res       Date:  2015-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.